Literature DB >> 26881345

[Auditory verbal hallucinations in patients with borderline personality disorder].

C Zonnenberg, M B A Niemantsverdriet, J D Blom, C W Slotema.   

Abstract

BACKGROUND: Traditionally, auditory verbal hallucinations (AVH) experienced by patients with a borderline personality disorder (BPD) are considered to be rare, to have a 'pseudo'-quality, and to cause little distress. AIM: To provide an overview of studies of the prevalence and phenomenological characteristics of AVHs in patients with a BPD, and of the ensuing degree of suffering.
METHOD: We performed a systematic literature search using PubMed and the Ovid database.
RESULTS: 27% of patients with a BPD experience AVH. Phenomenologically, these percepts are indistinguishable from those experienced by patients with a schizophrenia spectrum disorder. Hallucinations in several modalities were present in 50% of the patients with BPD. The mean time-span in which AVH were experienced was 17 years, the mean frequency was several minutes per day. The degree of suffering was high and the patient's life was interrupted to a moderate degree.
CONCLUSION: AVH and other hallucinations are common in BPD. We advise clinicians to inquire directly whether patients experience them and to provide treatment whenever possible. However, one of the problems is, that evidence-based treatment methods such as antipsychotics, cognitive-behavioural therapy and transcranial magnetic stimulation have not yet been studied systematically for this specific patient group.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26881345

Source DB:  PubMed          Journal:  Tijdschr Psychiatr        ISSN: 0303-7339


  1 in total

1.  Voice Hearing in Borderline Personality Disorder Across Perceptual, Subjective, and Neural Dimensions.

Authors:  Will H Strawson; Hao-Ting Wang; Lisa Quadt; Maxine Sherman; Dennis E O Larsson; Geoff Davies; Brontë L A Mckeown; Marta Silva; Sarah Fielding-Smith; Anna-Marie Jones; Mark Hayward; Jonathan Smallwood; Hugo D Critchley; Sarah N Garfinkel
Journal:  Int J Neuropsychopharmacol       Date:  2022-05-27       Impact factor: 5.678

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.